# A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10

> **NCT02482441** · PHASE1 · COMPLETED · sponsor: **OncoMed Pharmaceuticals, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Relapsed Tumors
- Refractory Solid Tumors

## Interventions

- **DRUG:** OMP-131R10
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT02482441
- **Lead sponsor:** OncoMed Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-16
- **Primary completion:** 2018-01-26
- **Final completion:** 2018-03-28
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02482441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02482441, "A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02482441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*